Vertex Phase IIb Data On Telaprevir Support 24-Week Dosing For Hepatitis C
This article was originally published in Pharmaceutical Approvals Monthly
Vertex released positive interim data from Phase IIb studies of its experimental protease inhibitor telaprevir for the treatment of hepatitis C Nov. 2 at the American Association of the Study of Liver Diseases meeting in Boston
You may also be interested in...
Vertex Pharmaceuticals expects to have data available from Phase III trials evaluating the protease inhibitor telaprevir in patients with hepatitis C by mid-2010, the company announced Jan. 23. The program was initiated in March
Vertex expects to complete enrollment in PROVE 3, its Phase IIb trial of the protease inhibitor telaprevir (VX-950), by the end of the second quarter and initiate Phase III trials of the hepatitis C agent in the second half of the year, Executive VP-Medicines Development John Alam told analysts during a Feb. 1 year-end earnings call.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.